TICKERNOMICS Sign up
Last Update: 2024-03-28 02:14:21
Kezar Life Sciences Inc. ( KZR ) https://www.kezarlifesciences.com
0.89USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-72.15%
KZR
SPY
32.74%
-85.51%
KZR
SPY
92.93%
-94.96%
KZR
SPY
224.41%
KZR
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
70.92
-110.71
1.39
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.84
10.13
0.38
-38.86
0.00
1.09
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-364.67
100.00
-361.62
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
7.1794
-302.17
-41.50
0.78
Other Earnings and Cash Flow Stats:
Kezar Life Sciences Inc. ( KZR ) Net Income TTM ($MM) is -76.44
Kezar Life Sciences Inc. ( KZR ) Operating Income TTM ($MM) is -89.01
Kezar Life Sciences Inc. ( KZR ) Owners' Earnings Annual ($MM) is 0.00
Kezar Life Sciences Inc. ( KZR ) Current Price to Owners' Earnings ratio is 0.00
Kezar Life Sciences Inc. ( KZR ) EBITDA TTM ($MM) is -86.35
Kezar Life Sciences Inc. ( KZR ) EBITDA Margin is -361.62%
Capital Allocation:
Kezar Life Sciences Inc. ( KZR ) has paid 0.00 dividends per share and bought back -5.410142 million shares in the past 12 months
Kezar Life Sciences Inc. ( KZR ) has reduced its debt by 13.76 million USD in the last 12 months
Capital Structure:
Kezar Life Sciences Inc. ( KZR ) Interest-bearing Debt ($MM) as of last quarter is 10
Kezar Life Sciences Inc. ( KZR ) Annual Working Capital Investments ($MM) are -9
Kezar Life Sciences Inc. ( KZR ) Book Value ($MM) as of last quarter is 187
Kezar Life Sciences Inc. ( KZR ) Debt/Capital as of last quarter is 5%
Other Balance Sheet Stats:
Kezar Life Sciences Inc. ( KZR ) has 35 million in cash on hand as of last quarter
Kezar Life Sciences Inc. ( KZR ) has 17 million of liabilities due within 12 months, and long term debt 10 as of last quarter
Kezar Life Sciences Inc. ( KZR ) has 72 common shares outstanding as of last quarter
Kezar Life Sciences Inc. ( KZR ) has 0 million USD of preferred stock value
Academic Scores:
Kezar Life Sciences Inc. ( KZR ) Altman Z-Score is -1.33 as of last quarter
Kezar Life Sciences Inc. ( KZR ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Kezar Life Sciences Inc. ( KZR ) largest shareholder is owning shares at 0.00 ($MM) value
Morningside Venture Investment(an insider) Sold 40000 shares of Kezar Life Sciences Inc. ( KZR ) for the amount of $275200.00 on 2023-02-06
18.63% of Kezar Life Sciences Inc. ( KZR ) is held by insiders, and 86.69% is held by institutions
Kezar Life Sciences Inc. ( KZR ) went public on 2018-06-21
Other Kezar Life Sciences Inc. ( KZR ) financial metrics:
FCF:-49.09
Unlevered Free Cash Flow:-85.72
EPS:-1.27
Operating Margin:-364.67
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-49.27
Beta:0.78
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Kezar Life Sciences Inc. ( KZR ) :
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.